Sanofi/AstraZeneca’s Nirsevimab Is Set To Transform RSV Treatment In Infants
Sanofi executives discuss ongoing efforts to make the monoclonal antibody available for the next RSV season and the impact it will have as the first prophylactic treatment for all infants. An FDA advisory committee is expected to discuss the biologics license application at a yet-to-be announced meeting.
You may also be interested in...
RSV Market Shake Up Starts As Sanofi And AZ’s Beyfortus Wins First Approval
The firms’ monoclonal antibody has received the EU green light just months after a positive CHMP opinion with observers projecting billions in peak sales as it becomes the first new RSV prophylactic in decades.
RSV Vaccine May Be On Market In 2023, CDC’s ACIP Anticipates
Panel expects to review five respiratory syncytial virus vaccines and vote on one or two of them in June 2023 and others four months later. Sanofi presents results of three clinical trials of its monoclonal antibody nirsevimab, which is on track to be the second RSV prophylaxis for infants.
Biopharma Industry Sharply Divided Over Supreme Court Antibody Patent Brawl
Big biologic makers line up on opposite sides of dispute between Amgen and Sanofi over whether Amgen’s Repatha patents cover analogous antibodies with the same functional characteristics.